Factors associated with undertreatment of atrial fibrillation in geriatric outpatients with Alzheimer disease

American Journal of Cardiovascular Drugs

Volumn 13, Issue 6, 2013, Pages 425-433

  Tavassoli, Neda ^a   Perrin, Amélie ^a   Bérard, Emilie ^a   Gillette, Sophie ^a,b   Vellas, Bruno ^a,b   Rolland, Yves ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADL DISABILITY; AGED; ALZHEIMER DISEASE; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAREGIVER; CEREBROVASCULAR ACCIDENT; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FALL RISK ASSESSMENT; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HOME CARE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMBULATORY CARE; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84890471702     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0040-5     Document Type: Article

References (39)

1. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104:2118-50.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. Circulation. 2006;114:700-52.
3. Haute Autorité de Santé (2007). Guide - affection de longue durée 2007: fibrillation auriculaire. http://www.has-sante.fr/portail/ upload/docs/application/pdf/ald-5-fibrillation-auriculaire.pdf. Accessed 22 Jul 2013.
4. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369-429.
5. Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010;27:39-50.
6. Vasishta S, Toor F, Johansen A, et al. Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. Arch Gerontol Geriatr. 2001;33:219-26.
7. Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians' and cardiologists' care for patients with heart failure. Am Heart J. 1999;138:826-34.
8. Lipton HL, Bero LA, Bird JA, et al. Undermedication among geriatric outpatients: results of a randomized controlled trial. Ann Rev Gerontol Ger. 1992;12:95-108.
9. Dinh T, Nieuwlaat R, Tieleman RG, Büller HR, van Charante NA, Prins MH, Crijns HJ. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in the Netherlands - the EXAMINE-AF study: a questionnaire survey. Int J Clin Pract. 2007;61:24-31.
10. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J, Mas JL, Gallai V, SAFE II Investigators. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004;57:798-806.
11. Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs Aging. 2002;19:819-46.
12. Villa A, Bacchetta A, Omboni E, et al. Underuse of antithrombotic therapy in stroke patients with chronic atrial fibrillation response. Stroke. 2000;21:2266-78.
13. Ceresne L, Upshur RE. Atrial fibrillation in a primary care practice: prevalence and management. BMC Fam Prac. 2002;3:11.
14. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S4-9.
15. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc. 1996;44:521-3.
16. Duron E, Hanon O. Atrial fibrillation and cognitive function. Psychol Neuropsychiatr Vieil. 2010;8:209-14.
17. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J. 2007;28:1962-7.
18. Edland SD, Rocca WA, Petersen RC, Cha RH, Kokmen E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol. 2002;59:1589-93.
19. Forti P, Maioli F, Pisacane N, Rietti E, Montesi F, Ravaglia G. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr. 2007;44(Suppl. 1):155-65.
20. Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, Anand IS, Hart R, Connolly SJ; Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) Investigators. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:277-83.
21. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. The REAL.FR research program on Alzheimer's disease and its management: methods and preliminary results. J Nutr Health Aging. 2003;7:91-6.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
23. The definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. J Auton Nerv Syst. 1996;58:123-4.
24. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-9.
25. Lawton MP, Brody EM. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-86.
26. Vellas BJ, Wayne SJ, Romero L, Baumgartner RN, Rubenstein LZ, Garry PJ. One-leg balance is an important predictor of injurious falls in older persons. J Am Geriatr Soc. 1997;45:735-8.
27. Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15:116-22.
28. Tilly-Gentric A. Anticoagulation in permanent atrial fibrillation after 75 years of age. Rev Med Interne. 2002;23:834-9.
29. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-9.
30. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160:967-73.
31. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822-7.
32. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long term care setting. Arch Intern Med. 1997;157:978-84.
33. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med. 1996;11:721-8.
34. Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther. 2003;25:1750-64.
35. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-34.
36. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
37. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-Study on Atrial Fibrillation (SCAF-study). Eur Heart J. 2006;27:1954-64.
38. Mehrabian S, Duron E, Labouree F, Rollot F, Bune A, Traykov L, Hanon O. Relationship between orthostatic hypotension and cognitive impairment in the elderly. J Neurol Sci. 2010;299:45-8.
39. Ingelgård A, Hollowell J, Reddy P, Gold K, Tran K, Fitzmaurice D. What are the barriers to warfarin use in atrial fibrillation? Development of a questionnaire. J Thromb Thrombolysis. 2006;21:257-65.